- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01839331
An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee
Study Overview
Status
Conditions
Detailed Description
A Randomized, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of two Doses of Intra-Articular Injection of Ampion™ in Adults with pain due to osteoarthritis of the knee.
The primary trial objective is to evaluate whether there is greater efficacy of 10 mL Ampion™ versus 10 mL placebo than 4 mL Ampion™ versus 4 mL placebo intra-articular (IA) injection in improving knee pain, when applied to patients suffering from OA of the knee.
The secondary trial objective include: the evaluation of the safety of an intra-articular injection of Ampion™ when applied to patients suffering from OA of the knee, evaluation of the efficacy of intra-articular injection of Ampion™ and placebo on stiffness and function when applied to patients suffering from OA of the knee and evaluation of responder status defined by the Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) Criteria.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to provide written informed consent to participate in the study
- Willing and able to comply with all study requirements and instructions of the site study staff
- Male or female, 40 years to 85 years old (inclusive)
- Must be ambulatory
- Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of osteoarthritis (OA) and supported by radiological evidence Kellgren Lawrence Grade II to IV) that is not older than 6 months prior to the date of screening
- Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale) assessed at screening
- Moderate to moderately-severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks prior to screening, have been/are being used)
- No analgesia (including acetaminophen [paracetamol]) taken 12 hours prior to an efficacy measure
- No known clinically significant liver abnormality e.g. cirrhosis, transplant, etc.)
Exclusion Criteria:
- As a result of medical review and screening investigation, the Principal Investigator considers the patient unfit for the study
- A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)
- A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)
- Presence of tense effusions
- Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator
- Isolated patella femoral syndrome, also known as chondromalacia
- Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial e.g. cancer, congenital defects, spine OA)
- Major injury to the index knee within the 12 months prior to screening
- Severe hip OA ipsilateral to the index knee
- Any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)
- Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study
Use of the following medications:
- No IA injected pain medications in the study knee during the study
- No analgesics containing opioids. NSAIDs may be continued at levels preceding the study and acetaminophen is available as a rescue medication during the study from the provided supply
- No topical treatment on osteoarthritis index knee during the study
- No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as Aspirin and Plavix are allowed)
- No systemic treatments that may interfere with safety or efficacy assessments during the study
- No immunosuppressants
- No use of corticosteroids > 10 mg prednisolone equivalent per day (if ≤ 10 mg prednisolone, the dose must be stable)
- Any human albumin treatment in the 3 months before randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ampion 4 mL Dose
4 mL Injection of Ampion
|
4 mL Injection of Ampion
|
Placebo Comparator: Placebo 4 mL Dose
4 mL Injection of Placebo
|
4 mL Injection of Placebo
Other Names:
|
Experimental: Ampion 10 mL Dose
10 mL Injection of Ampion
|
10 mL Injection of Ampion
|
Placebo Comparator: Placebo 10 mL Dose
10 mL Injection of Placebo
|
10 mL Injection of Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Knee Pain
Time Frame: Scored at Baseline and 12 weeks
|
Mean Change in WOMAC A Pain (Western Ontario and McMaster Universities Arthritis Index) score from Baseline to 12 weeks.
5-point Likert scale (0=none to 4=extreme).
A negative difference constitutes a decrease in pain with a greater negative value indicating a greater reduction in pain.
|
Scored at Baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Knee Function
Time Frame: Scored at Baseline and 12 weeks.
|
Mean change in WOMAC C function score (Western Ontario and McMaster Universities Arthritis Index) from Baseline to 12 weeks.
5-point Likert scale indicating limitation of function (0=none to 4=extreme).
A greater negative value indicates a improvement in function.
|
Scored at Baseline and 12 weeks.
|
Change in Knee Stiffness.
Time Frame: Scored at Baseline and 12 weeks.
|
Mean Change in WOMAC B stiffness score from Baseline to 12 weeks.
5-point Likert scale (0=none to 4=extreme).
A negative difference constitutes a reduction in stiffness.
|
Scored at Baseline and 12 weeks.
|
Change in Patient's Global Assessment
Time Frame: Scored at Baseline and 12 weeks.
|
Patients are asked the following question: "Considering all the ways in which your arthritis affects you, please indicate how you are doing."
5-point Likert scale (0 = very well, 1 = well, 2 = fair, 3 = poor, 4 = very poor).
A negative value constitutes an improvement in patient's assessment of disease severity.
|
Scored at Baseline and 12 weeks.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AP-003-A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of the Knee
-
Taiwan Liposome CompanyCompletedOSTEOARTHRITIS OF THE KNEETaiwan, United States
-
University Hospital, GhentCompletedOsteoarthritis of the Knee JointBelgium
-
Bone Therapeutics S.ANordic Bioscience A/SCompletedSymptomatic Osteoarthritis of the KneeDenmark, Belgium, United Kingdom, Czechia, Hong Kong, Moldova, Republic of, Poland
-
Rush University Medical CenterWithdrawnSymptomatic Osteoarthritis of the Knee
-
Region SkaneRecruitingOsteoarthritis of the Knee or HipSweden
-
UMC UtrechtCompletedMedial Compartment Osteoarthritis of the KneeNetherlands
-
Massachusetts General HospitalGöteborg University; Seoul National University Hospital; Ulsan University Hospital and other collaboratorsUnknownOsteoarthritis of the Knee | Traumatic Arthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
Hospital General de Jerez de la FronteraZiekenhuis Oost-LimburgCompletedPainful Osteoarthritis of the KneeSpain
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
Clinical Trials on 4 mL Injection of Placebo
-
Ampio Pharmaceuticals. Inc.CompletedOsteoarthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.Completed
-
Ampio Pharmaceuticals. Inc.CompletedOsteoarthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.CompletedKnee Osteoarthritis | Osteoarthritis, Knee | Knee Arthritis | Knee Pain ChronicUnited States
-
Ampio Pharmaceuticals. Inc.CompletedOsteoarthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
AbbottMassachusetts General Hospital; Harvard UniversityTerminatedHypertrophy, Left Ventricular | Chronic Kidney Disease (CKD) Stage 5Italy, United States, Taiwan, Poland, United Kingdom, Greece, Germany, Russian Federation, Spain, Australia, Czech Republic, Puerto Rico, Romania
-
Adynxx, Inc.CompletedPostsurgical PainUnited States
-
Adynxx, Inc.National Institute on Drug Abuse (NIDA)Withdrawn
-
Shanghai Henlius BiotechActive, not recruitingMetastatic Colorectal Cancer (mCRC)China